Assuming that litigated patents are valuable, the incidence of litigation for patents protecting biologics (146 patents), small molecules (1822) or issued to drug-discovery companies per se (1929) was examined. This was done by accessing the litigation database of the company MaxVal Group Inc. (20%) of those protecting biologics, 40% protecting small molecules and 1% of those issued to the companies were litigated (although only 0.3% of those issued to companies that do not protect biologics or small molecules). The average time between the grant of a patent and its first litigation was 15.7, 7.8 and 2.7 (2.0) years respectively. Thus, the relevant patents of this study were litigated much later than the average litigated patent. Each litigated patent was litigated 1.7, 5.6 and 2.4 (1.0) times respectively. In each category, most litigants were companies, with very few litigations involving academic institutions or the USPTO, and no non-profit organizations. These results should be of interest to drug-discovery companies, to those who fund or acquire such companies and to non-profit drugdiscovery centres.
Patents are contentious. It is often claimed that they are vital to incentivize innovation, 1 but this view point has been challenged. Those who oppose patents claim that there are many examples of innovation without them and that they are merely a State-sanctioned monopoly to protect the commercial interests of their owners. 2 Surveys have shown that all industries do not regard patents as equally valuable. 3 There is agreement, however, that they are important for the pharmaceutical and biotechnology industries. 3, 4 These industries often charge very high prices for the drugs protected by patents, and this has also become controversial. Whereas, industry claims that these prices protect their investment in research and development, 5, 6 health activists lament the fact that the cost of medicines can drive patients into poverty. 7, 8 Controversy notwithstanding, patents are important for the pharmaceutical and biotechnology industries. This raises the question 'How important?'. Various factors are considered to reflect the importance or value of a patent. These are (i) the number of claims, 9 (ii) whether maintenance fees are paid, 9 (iii) the number of forward citations, 9 (iv) whether the patent has been litigated 10 , and for a pharma patent, (v) whether it has been protected in two of the three major pharma markets, the US, Europe and Japan. 11 To remain 'valid' or 'in force', a patent needs to be maintained. For patents issued by the United States Patent and Trademark Office (USPTO), maintenance fees, totaling thousands of dollars, need to be paid at three payment 'windows', that is 3.5, 7.5 and 11.5 years after issue. 12 If a patent is maintained, this implies that it is valuable to its owner. In an earlier study 13 it has been shown that patents protecting biologics or small molecules were almost invariably maintained whereas those assigned to drug discovery companies per se were maintained much less. Litigation, too, has costs, and in 2001 it was estimated that the median cost of litigating a US patent is upward of $1.5 million per side. 10 Thus, if a patent is litigated, one may conclude that it is considered valuable by others.
Given these costs, those involved in drug discovery would want to know whether or not drug-related patents are litigated. This question has been examined using the same three sets of patents (3,897 overall) for which maintenance was examined in the earlier study, that is those (a) protecting biologics, (b) protecting small molecules and (c) issued to drug discovery companies irrespective of whether or not they protect the drug. All of these patents were issued by the USPTO and the concerned drugs were those approved by the US Food and Drug Administration (USFDA). It has been determined whether or not each patent was litigated. For each litigated patent, the average time to litigation, the average number of times it was litigated and the types of organizations that were involved in the litigation was determined.
Methods
The three data sets were created and processed as described below. The patent services company MaxVal Group Inc.
14 provided access to its Litigation Databank 15 which was used to analyze all the patents of this study. The Databank was accessed between February and June 2015 (inclusive).
Biologics
The list of 146 patents that protected biologics was taken from the earlier work. 13 Each patent was checked at the Litigation Databank and if it had been litigated, the following nine details were obtained from the Databank: (i) names of litigants, (ii) court, (iii) date of filing of case, (iv) duration of litigation (in days), (v) whether the case is closed or still open, (vi) number of patents involved in the case, (vii) product that the patent protects, (viii) type of case and (ix) basis of termination of case (where applicable). Then, the following details about each litigated patent were collected from the USPTO 16 : (a) assignee, (b) patent application date (PCT application date if relevant), (c) whether the patent was a PCT application and (d) patent issue date. Finally, for patents litigated more than once, the earliest litigation filing date was identified and the number of years between the 'patent issue date' and the earliest 'litigation filing date' for each patent was calculated. However, for a given patent, if even one 'date of filing of case' was not provided, the 'number of years between the date of patent issue and the earliest litigation' for the patent was not calculated (even if the dates of filing of other cases for that patent were available) since one could not identify the earliest. The list of litigated patents, the number of cases of each and some of the other details mentioned above are provided in Table 1 .
Small molecules
The list of 1,833 patents that protected small molecules was also taken from the earlier work. 13 11 of these are marked 'PED'. However, this is not part of the original patent number issued by the USPTO, and instead is a notation by the FDA to indicate pediatric versions of drugs that the patent protects. These 11 patents were removed, to yield a list of 1,822. These patents were processed at the Litigation Databank as the biologic-related patents had been. The issue of 'earliest litigation date' was also handled as for the biologic-related patents. The list of litigated patents, the number of cases of each and other details are provided in Table 2 for the first 500 litigations (connected with 99 patents). However in one case, 5827529, only the earliest two out of three cases were taken to get the round figure of 500 litigations.
Companies
This set of patents comprises those that are issued to drug discovery companies per se, and may or may not protect a small molecule or biologic drug. Here, two sets of patents were analyzed. (i) Earlier 13 the maintenance of 443 patents was examined. These correspond (with some riders) to the patents issued to drug discovery companies starting with the letters A to E of a previous paper from our group. 17 Four of the 443 patents were duplicates, so, first the litigation status of the remaining 439 patents was investigated. Very few patents were litigated. (ii) To confirm this result, a larger set of patents was examined. The list of 59 companies was re-examined. 17 Firstly, the patents of the three companies that had over 100 patents at the time of that study (Cytokinetics, Lexicon Pharmaceuticals and Millennium Pharmaceuticals) were examined. Then, every fifth company was considered (of which Cytokinetics and Lexicon Pharmaceuticals overlapped the earlier set of three). Overall, the patents of 13 companies were considered (Table 3a) in set (ii). To date 1,649 patents have been issued to these companies. Of these, 159 overlapped the 439 patents of set (i). Thus, overall, 1,929 company-related patents were investigated. The company-related patents were processed at the Litigation Databank as the biologicand small molecule-related patents had been. The issue of 'earliest litigation date' was also handled in the same manner. The USPTO was accessed in the first week of March 2015. Some of the 1,929 patents had been litigated. In order to check whether any of them were linked to small molecules, the FDA's list of patents that protect such molecules was accessed. The file, which was available at Orange Book Data Files from the FDA website, was downloaded on 8 March 2015. 18 The zipped folder contained three files, of which patent.txt provided the required information. In set (i): The three litigated patents from the set of 439 were assigned to Cubist Pharmaceuticals (two, with nine litigations each) and CardioVascular BioTherapeutics (one, with one litigation). In set (ii): The list of 13 companies, the number of patents issued to each, the number of those that were litigated, and the number of litigations per litigated patent. The list of litigated patents, the number of cases of each and other details are provided in Table 3 .
Results
For patents, protecting biologics, small molecules, issued to drug discovery companies per se details of those that were litigated are summarized in Table 4 . In the absence of further details, even 'et al. ' cases were considered to have just one litigant each. For small molecule patents, a subset of 500 litigations were analyzed in greater detail (column C). For companies, the subset of litigated patents that do not protect biologics or small molecules were analyzed separately (column E).
Of the 146 patents that protected biologics, 29 (19.9%) were litigated a total of 49 times (Tables 1a,  1c, 4) . Thus, there were 1.7 cases per litigated patent. The average time from grant of the patent to its earliest litigation was 15.7 years for 28 cases, with one case not determinable. The 49 cases had 98 litigants (including one case of 'et al. ' ). Most of them were companies, with the International Trade Commission listed once, the University of Iowa thrice and individuals 24 times (Table 1b) . Amongst the individuals, David J. Kappos, a former Director of the USPTO, was listed once. It could not be ascertained whether the other individuals represented companies or other institutions.
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Of the 1,929 patents issued to drug discovery companies, only 19 (1%) were litigated, a total of 46 times (Tables 3b, 3c, 4) . Thus there have been 2.4 litigations per litigated patent. The average time from patent issue to its earliest litigation was 2.7 years for the 19 patents. The 46 cases had 92 litigants (with no case of 'et al. ' ), most of which were companies. There were no university litigants. Individuals were listed six times including Teresa Stanek Rea thrice and David J Kappos twice.
Of these 19 patents, only five (0.3% of the total) did not protect a small molecule or biologic (Table 4) . These five were litigated once each, and the average time from the grant of the patent to its earliest litigation was 2.0 years (for all five). Amongst the 10 litigants, most were companies. There were no universities, but four mentions of individuals including Teresa Stanek Rea (once) and David J Kappos (twice).
Discussion
There are several insights from this study. First, there is a clear difference in the litigation rates of (a) patents that protect biologics, (b) those that protect small molecules and (c) those that are issued to drug discovery companies but that do not protect any molecule on the market. It is clear from the data that cases (a) and (b), but not (c), face significant litigation. In case (c), there is negligible litigation which implies that the patents are of little commercial interest to others, which is unsurprising considering that they do not protect any product on the market. As, it has been shown in earlier work, 17 the number of patents issued to a drug discovery company may range from zero to several hundred. Even if a company has several hundred patents, the absence of litigation indicates a lack of interest in most of these patents by others. This makes the argument that patents are very important for the pharma industry 3, 4 more nuanced. That is patents are crucial, but the large numbers that even R&D pharma companies sometimes possess is not a true quantification of this.
The negligible litigation rates demonstrate this even more powerfully than the maintenance rates, where 65% or more of company-issued patents were maintained at each payment window, 13 indicating that the patents are considered important by the owner. In future, it would be interesting to examine how much the other factors that are thought to reflect the importance of a patent (the number of claims, 9 the number of forward citations 9 and the major pharma markets in which it is obtained 11 ) actually do so for bio-medical patents. Second, other researchers have found that if a patent was litigated, this litigation usually happened soon after the patent was issued. 10 It has been found that this held true for patents issued to companies individual cases may take longer due to longer development time or longer approval times at the FDA. This would especially be so if there is an extremely novel biologic where there is no precedent of regulatory approval for that class of molecules. In fact, a very recent news item 20 describes litigation brought by Amgen against Sandoz that wishes to bring out a biosimilar version of Enbrel. The five contested patents were issued in 2011, 2012 and 2014. Litigation has just started, in February 2016. This is further confirmation that after 2010, litigation around biologics is likely to happen sooner than it has been in the past.Coming to case (b), that is small molecules: Small molecules have been on the market for decades longer than biologics. There is a well known regulatory path for generics to enter the market and also many more generics firms. Here too, much litigation concerns generic competitors and there are 5.6 litigants per litigated patent compared to just 1.7 for biologics, a reflection of the larger number of generic competitors in the small molecule space. It was common to see well known generics companies such as Teva, Dr Reddy's Laboratories, Mylan Pharmaceuticals, Sun Pharmaceutical Industries Limited and Glenmark Pharmaceuticals Inc. listed as litigants.
Finally, in all three categories, most litigants were companies, with very few cases involving the USPTO or academic institutions, and no non-profit organizations as far as can be determined. This implies that commercially useful patents are with companies, and are also of interest only to other companies. Thus, for instance, non-profit consortia that may be interested in drug development are not involved in litigations around such patents.
Conclusion
Almost 4000 patents related to biologic-or smallmolecule drugs, or issued to companies working in this area have been analyzed. There is a distinct difference in the litigation rates of patents protecting each of the three sets of patents. Biologics-related patents described herein are litigated after several years of issue, a fact closely linked to the US law in 2010 that cleared the way for a pathway to approve biosimilars. Further, it is mainly companies that are involved in litigation. These insights should be of interest to drug discovery companies and those who acquire them or in-license assets from them, to those who fund such companies and also to non-profit centers involved in drug discovery.
